Read more...

Mesothelioma Progression and Evaluation Read more...

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for Stage IV (metastatic) sarcomas in the “Practice Guidelines in Oncology ” (V.2.2010), … The published study results demonstrated that the addition of regional hyperthermia, using the BSD-2000 Hyperthermia System, to chemotherapy (EIA) resulted in a significant reduction in disease progression or death, with a median … Read more...

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found. Read more...

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found. Dr P… Read more...

The Lancet Oncology , the premier worldwide journal for original oncology research, published the results of this Phase III clinical study of hyperthermia, “Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high- risk … The published study results demonstrated that the addition of regional hyperthermia, using the BSD-2000 Hyperthermia System, to chemotherapy (EIA) resulted in a significant reduction in disease progression or death, with a median … Read more...

A key attribute of studies in genetically modified models of cancer, as provided by the OncoMouse® technology, is the ability to study tumor progression in the microenvironment of the surrounding tissues and to study the molecular and … Read more...

Patients were switched to continuous androgen deprivation at disease progression or with a PSA of more than 10 ng/ml within 2 months of discontinuing therapy. Dr. Christopher Logothetis, chair of genitourinary medical oncology at MD … Read more...

… has been linked to breast cancer progression , but the molecular details of that connection were unknown,” said senior author Mien-Chie Hung, Ph.D., professor and chair of MD Anderson’s Department of Molecular and Cellular Oncology Read more...

The primary endpoint was median time to tumor progression . Secondary endpoints included objective tumor response rate (WHO criteria), measured every 3 mos, as well as symptom control and overall survival Results: Eighty-five patients … Read more...